REG - Medpal AI PLC - MedPal App: AI Integration with MedPal Clinic

Medpal AIAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260108:nRSH0751Oa&default-theme=true

RNS Number : 0751O  Medpal AI PLC  08 January 2026

8 January 2026

MedPal AI plc

("MedPal AI" or the "Company")

MedPal App: AI Integration with MedPal Clinic

 

UK-First: AI-Powered Health App to Pharmacy Integration

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company, is pleased to announce the launch of what the Directors
believe to be a UK-first: direct AI integration between a consumer health app
and a regulated pharmacy, enabling intelligent, personalised clinical pathways
for [health and] weight management.

MedPal app and MedPal Clinic Integration

Further to the Company's announcement of a significant update to the MedPal
app on 8 December 2025, the board is pleased to announce a further
development. The MedPal app's AI now analyses aggregated user health data,
including body mass index ("BMI"), to identify individuals who may benefit
from clinically supervised weight management and GLP-1 treatments or other
supplements or medicines that can be obtained via the Company's online MedPal
Clinic. The Company believes it is the first to offer this level of AI
integration between a pharmacy and a health and wellness app.

Intelligent Targeting

The AI identifies key indicators including slow or blocked metabolism, weight
loss goals, and hunger control concerns. Crucially, the system only suggests
GLP-1 assessment pathways to users whose BMI qualifies them for clinical
evaluation, ensuring responsible, targeted healthcare rather than blanket
advertising.

The Company intends to expand this intelligent targeting to include all
medications that can be prescribed and dispensed at MedPal Pharmacy, including
the full range of men's and women's health medications that an Independent
Prescriber can prescribe under the Electronic Prescription Drug Guidance
("ePDG") regulations in the UK.

Seamless Deployment

The enhancement deploys entirely through the AI backend, requiring no app
update. Eligible users receive a direct pathway to MedPal Clinic's assessment
page with a 30% introductory discount (code: MEDPALAPP). MedPal Clinic can
also become the user's designated pharmacy for any other private or NHS
prescriptions, offering fast and flexible fulfilment through its state of the
art, automated 24/7 distribution centre and rapid nationwide delivery.

Revenue Driver

This integration demonstrates the Company's dual-engine model in action: the
AI-driven wellness app generating demand whilst the regulated pharmacy
services fulfil clinical needs. By leveraging aggregated health data to
provide personalised pathways, MedPal AI continues to differentiate itself in
the rapidly expanding UK weight management and pharmaceutical market.

Jason Drummond, Chief Executive Officer, commented:

"We believe that this is a UK-first and that no other pharmacy has this depth
of AI integration with a health app. Our system doesn't just advertise health
supplements and weight loss treatments; it understands each user's health
profile and only connects those who clinically qualify with our GLP-1
prescribing services. This is the future of personalised healthcare, and
MedPal is leading it."

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUPURWGUPQPUM



            Copyright 2019 Regulatory News Service, all rights reserved